期刊文献+

miR‑28‑3p在多发性骨髓瘤中的研究现状

Research status of miR-28-3p in multiple myeloma
暂未订购
导出
摘要 多发性骨髓瘤(multiple myeloma,MM)的形成是一个涉及多种生物学因素和分子机制相互作用的复杂过程,与多种信号通路、肿瘤微环境(tumor micro-environment,TME)之间的相互作用密切相关。微小RNA(microRNA,miRNA)是一类高度稳定的小型非编码RNA,miR⁃28⁃3p作为其重要一员,通过诱导磷酸酶和张力蛋白同源基因(phosphatase and tensin homolog deleted on chromosome ten,PTEN)的表达及其他重要细胞因子的产生,在调控细胞增殖、凋亡、侵袭及转移等重要环节发挥其功能。本文结合国内外研究对miR⁃28⁃3p的作用机制进行综述,有助于阐明miR⁃28⁃3p在MM的发生、发展过程中发挥的重要作用及其分子机制,为其在MM的基因诊断、治疗靶标开发方面提供了新的理论依据和潜在靶点。 The formation of multiple myeloma is a complex process involving the interaction of multiple biological factors and molecular mechanisms,which is closely related to the interaction between multiple signaling pathways and tumor micro-environment(TME).MicroRNA(miRNA)is a highly stable class of small non-coding RNAs.As an important member,miR-28-3p shows its characteristics in multiple myeloma by inducing the production of PTEN gene and other important cytokines,and regulates cell proliferation,apoptosis,invasion and metastasis.This article reviews the mechanism of action of miR-28-3p based on domestic and foreign studies,which is helpful to elucidate the important role played by miR-28-3p in the emergence and gradual development of multiple myeloma and the molecular mechanism behind it,and provides a new theoretical basis and potential targets for the genetic diagnosis and therapeutic target development of multiple myeloma.
作者 贾怡婷 李光耀 张丽 JIA Yiting;LI Guangyao;ZHANG Li(Department of Postgraduates,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250117,China;Department of Hematology,Liaocheng Affiliated Hospital of Shandong First Medical University(Liaocheng People’s Hospital),Liaocheng 252000,China)
出处 《山东第一医科大学(山东省医学科学院)学报》 2025年第5期271-275,共5页 Journal of Shandong First Medical University & Shandong Academy of Medical Sciences
基金 国家自然科学基金(81573772) 山东省医药卫生科技发展计划(202203040757)。
关键词 多发性骨髓瘤 miR⁃28⁃3p 机制 信号通路 肿瘤微环境 multiple myeloma miR-28-3p mechanism signaling pathways tumor micro-environment
  • 相关文献

参考文献18

二级参考文献56

  • 1Jinyi Liu,Liwen Ren,Sha Li,Wan Li,Xiangjin Zheng,Yihui Yang,Weiqi Fu,Jie Yi,Jinhua Wang,Guanhua Du.The biology,function,and applications of exosomes in cancer[J].Acta Pharmaceutica Sinica B,2021,11(9):2783-2797. 被引量:68
  • 2黄丽,齐洁,崔建国,马慧,王园园,徐文文,常冀杨,刘美玲,杨倩倩,张清潭.中性粒细胞/淋巴细胞比值与慢性心力衰竭急性发作患者院内死亡的相关性研究[J].临床心血管病杂志,2020,36(2):138-142. 被引量:24
  • 3YAO Y, DONG Y, LIN F, et al. The expression of CRM1 is associated with prognosis in human osteosarcoma[J]. Oncol Rep, 2009, 21(1): 229-235.
  • 4GUARINO M, MICHELI P, PALLOTFI F, et al. Pathological relevance of epithelial and mesenchymal phenotype plasticity[J]. Pathol Res Pract, 1999, 195(6): 379-389.
  • 5GORLICK R, ANDERSON P, ANDRULIS I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary[J]. Clin Cancer Res, 21303, 9(15): 5442-5453.
  • 6WITTIG JC, BICKELS J, PRIEBAT D, et al. Osteosarcoma: a multidisciplinary approach to diagttosis and treatment[J]. Am Fam Physician, 2002, 65(6): 1123-1132.
  • 7YIN K, LIAO Q, ZHONG D, et al. Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture[J]. Exp Ther Med, 2012, 4(5): 889-894.
  • 8LIU J, RUAN B, YOU N, et al. Downregulation of miR-200a Induces EMT Phenotypes and CSC-like Signatures through Targeting the beta-catenin Pathway in Hepatic Oval Cells [J]. PLoS One, 2013, 8(11): e79409.
  • 9YANG G, YUAN J, LI K. EMT transcription factors: implication in osteosarcoma [J]. Medical Oncology (Northwood, London, England), 2013, 30(4): 697.
  • 10VALASTYAN S, WEINBERG RA. Tumor metastasis: molecular insights and evolving paradigms[J]. Cell, 2011, 147(2): 275-292.

共引文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部